Neurology & CNS · Phase III

Top sponsors

• HOFFMANN-LA ROCHE 21 programs
• Teva Pharma 12 programs
• Novartis India 10 programs
• Takeda 10 programs
• Bristol-Myers Squibb Australia 9 programs
• Jazz Pharmaceuticals Ireland 7 programs
• Biogen 6 programs
• TG THERAPEUTICS 6 programs
• Acadia Pharmaceuticals 5 programs
• Anaxis Pharma 5 programs
• NEUROCRINE BIOSCIENCES 5 programs
• SUPERNUS PHARMACEUTICALS 5 programs

1. C24-50

   The George Institute

   Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

   phase 3 · small molecule · active

   1 trial →

2. CBAF312D2301

   Novartis Pharmaceuticals

   Multiple Sclerosis in pediatric patients

   phase 3 · small molecule · active

   1 trial →

3. CEP-1347 10mg

   Teva Pharma GmbH

   Parkinson Disease

   phase 3 · small molecule · terminated

   1 trial →

4. CFTY720D2311

   Novartis Pharmaceuticals

   Multiple Sclerosis

   phase 3 · small molecule · active

   1 trial →

5. CLOU064C12301

   Novartis Pharmaceuticals

   Multiple Sclerosis

   phase 3 · small molecule · active

   1 trial →

6. CLOU064C12302

   Novartis Pharmaceuticals

   Multiple Sclerosis

   phase 3 · small molecule · active

   1 trial →

7. CLOU064C12306

   Novartis Pharmaceuticals

   Relapsing multiple sclerosis

   phase 3 · small molecule · active

   1 trial →

8. CLOU064P12301

   Novartis Pharmaceuticals

   Secondary progressive multiple sclerosis

   phase 3 · small molecule · active

   1 trial →

9. CN012-0023

   Bristol-Myers Squibb Australia Pty Ltd

   Agitation Associated with Alzheimer’s Disease

   phase 3 · small molecule · active

   1 trial →

10. CN012-0024

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 · small molecule · active

    1 trial →

11. CN012-0025

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 · small molecule · active

    1 trial →

12. CN012-0051

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 · small molecule · active

    1 trial →

13. CN012-0052

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 · small molecule · active

    1 trial →

14. CN0120020

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 · small molecule · active

    1 trial →

15. CN0120056

    Bristol-Myers Squibb Australia Pty Ltd

    Psychosis Associated with Alzheimer’s Disease

    phase 3 · small molecule · active

    1 trial →

16. CN42097

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 3 · small molecule · active

    1 trial →

17. COMB157G23101

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 · small molecule · active

    1 trial →

18. COMB157G2399

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis (RMS)

    phase 3 · small molecule · active

    1 trial →

19. COMB157G3301

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 · small molecule · active

    1 trial →

20. Cladribine (MAVENCLAD®)

    United Therapeutics Europe Ltd

    Advanced Multiple Sclerosis

    phase 3 · small molecule · active

    1 trial →

21. Crenezumab

    Hoffmann-La Roche

    Alzheimer's Disease

    phase 3 · small molecule · terminated

    1 trial →

22. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 · small molecule · active

    1 trial →

23. Dipraglurant

    Addex Therapeutics

    Parkinson Disease

    phase 3 · small molecule · terminated

    2 trials →

24. EFC16035

    Genzyme Europe B.V.

    Primary Progressive Multiple Sclerosis

    phase 3 · small molecule · active

    1 trial →

25. EFC17919A

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 · other · active

    1 trial →

26. EFC17919B

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 · small molecule · active

    1 trial →

27. EP0224

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy, Juvenile Absence Epilepsy

    phase 3 · small molecule · active

    1 trial →

28. Escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mild-to-moderate Depression

    phase 3 · small molecule · completed

    1 trial →

29. Eslicarbazepine acetate (BIA 2-093)

    Bial Portela & Companhia S.A.

    Partial Epilepsy in Children and Adolescents

    phase 3 · small molecule · completed

    1 trial →

30. Fingolimod

    Novartis Pharmaceuticals

    Multiple Sclerosis (MS)

    phase 3 · small molecule · active

    1 trial →

31. Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 3 · small molecule · active

    1 trial →

32. GA 20 mg/mL

    Teva Pharma GmbH

    Relapsing-Remitting Multiple Sclerosis

    phase 3 · small molecule · completed

    1 trial →

33. GN41791

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 · other · active

    1 trial →

34. GV-971

    Shanghai University of Traditional Chinese Medicine

    Alzheimer Disease

    phase 3 · small molecule · on hold

    1 trial →

35. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 · small molecule · completed

    4 trials →

36. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 · small molecule · completed

    5 trials →

37. GWP42003-P 20 mg/kg/Day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 · small molecule · completed

    3 trials →

38. Gantenerumab

    Hoffmann-La Roche

    Alzheimer Disease

    phase 3 · small molecule · terminated

    1 trial →

39. Glatiramer Acetate (DB)

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 · small molecule · completed

    1 trial →

40. Glatiramer Acetate (GA) 40 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 · small molecule · completed

    1 trial →

41. Glatiramer Acetate 20 mg/0.5 mL

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 · small molecule · completed

    1 trial →

42. Glatiramer acetate (GA)

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 · small molecule · completed

    1 trial →

43. I5T-MC-AACO

    Eli Lilly Co.

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    phase 3 · small molecule · active

    1 trial →

44. IM047-050

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsing Remitting Multiple Sclerosis

    phase 3 · small molecule · active

    1 trial →

45. INTENSIFY BD

    Disc Medicine

    Bipolar depression

    phase 3 · small molecule · active

    1 trial →

46. Iclepertin

    Boehringer Ingelheim

    Schizophrenia

    phase 3 · small molecule · terminated

    2 trials →

47. Intravenous Carbamazepine (IV CBZ)

    LIGAND PHARMACEUTICALS INC

    Epilepsy

    phase 3 · small molecule · completed

    1 trial →

48. Intravenous Immunoglobulin

    Option Therapeutics

    Autoimmune Epilepsy

    phase 3 · small molecule · terminated

    1 trial →

Frequently asked questions